Non-insulin treatments for diabetes

Eugenio Angueira

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aimed to review newer therapeutic agents for the treatment of diabetes that are related to hormones responsible for glucose metabolism other than insulin. Data from several new therapeutic agents were reviewed to provide an overview of the efficacy and tolerability of these agents. With a greater understanding of the physiology of glucose homeostasis and the pathophysiology of diabetes, new therapeutic agents have been developed to address other hormonal deficiencies/defects that are seen in the disease. These new agents fall under the categories of incretin-related therapies, such as glucagon-like peptide-1 mimetics, glucagon-like peptide-1 analogs, dipeptidyl peptidase-4 inhibitors, and amylin analogs. A1c reductions with these agents range from 0.4% to 1.6% (depending on each agent), with added benefits such as weight neutrality/loss and low risk for hypoglycemia.

Original languageEnglish
Pages (from-to)376-383
Number of pages8
JournalAmerican Journal of Therapeutics
Volume20
Issue number4
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Glucagon-Like Peptide 1
Dipeptidyl-Peptidase IV Inhibitors
Islet Amyloid Polypeptide
Incretins
Glucose
Therapeutics
Hypoglycemia
Weight Loss
Homeostasis
Hormones
Insulin

Keywords

  • Exenatide
  • GLP-1
  • Incretin
  • Liraglutide
  • Pramlintide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Non-insulin treatments for diabetes. / Angueira, Eugenio.

In: American Journal of Therapeutics, Vol. 20, No. 4, 01.07.2013, p. 376-383.

Research output: Contribution to journalArticle

Angueira, Eugenio. / Non-insulin treatments for diabetes. In: American Journal of Therapeutics. 2013 ; Vol. 20, No. 4. pp. 376-383.
@article{338dd09b0cf64e25b6cf3c0c1693a216,
title = "Non-insulin treatments for diabetes",
abstract = "Aimed to review newer therapeutic agents for the treatment of diabetes that are related to hormones responsible for glucose metabolism other than insulin. Data from several new therapeutic agents were reviewed to provide an overview of the efficacy and tolerability of these agents. With a greater understanding of the physiology of glucose homeostasis and the pathophysiology of diabetes, new therapeutic agents have been developed to address other hormonal deficiencies/defects that are seen in the disease. These new agents fall under the categories of incretin-related therapies, such as glucagon-like peptide-1 mimetics, glucagon-like peptide-1 analogs, dipeptidyl peptidase-4 inhibitors, and amylin analogs. A1c reductions with these agents range from 0.4{\%} to 1.6{\%} (depending on each agent), with added benefits such as weight neutrality/loss and low risk for hypoglycemia.",
keywords = "Exenatide, GLP-1, Incretin, Liraglutide, Pramlintide",
author = "Eugenio Angueira",
year = "2013",
month = "7",
day = "1",
doi = "10.1097/MJT.0b013e318235f2cb",
language = "English",
volume = "20",
pages = "376--383",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Non-insulin treatments for diabetes

AU - Angueira, Eugenio

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Aimed to review newer therapeutic agents for the treatment of diabetes that are related to hormones responsible for glucose metabolism other than insulin. Data from several new therapeutic agents were reviewed to provide an overview of the efficacy and tolerability of these agents. With a greater understanding of the physiology of glucose homeostasis and the pathophysiology of diabetes, new therapeutic agents have been developed to address other hormonal deficiencies/defects that are seen in the disease. These new agents fall under the categories of incretin-related therapies, such as glucagon-like peptide-1 mimetics, glucagon-like peptide-1 analogs, dipeptidyl peptidase-4 inhibitors, and amylin analogs. A1c reductions with these agents range from 0.4% to 1.6% (depending on each agent), with added benefits such as weight neutrality/loss and low risk for hypoglycemia.

AB - Aimed to review newer therapeutic agents for the treatment of diabetes that are related to hormones responsible for glucose metabolism other than insulin. Data from several new therapeutic agents were reviewed to provide an overview of the efficacy and tolerability of these agents. With a greater understanding of the physiology of glucose homeostasis and the pathophysiology of diabetes, new therapeutic agents have been developed to address other hormonal deficiencies/defects that are seen in the disease. These new agents fall under the categories of incretin-related therapies, such as glucagon-like peptide-1 mimetics, glucagon-like peptide-1 analogs, dipeptidyl peptidase-4 inhibitors, and amylin analogs. A1c reductions with these agents range from 0.4% to 1.6% (depending on each agent), with added benefits such as weight neutrality/loss and low risk for hypoglycemia.

KW - Exenatide

KW - GLP-1

KW - Incretin

KW - Liraglutide

KW - Pramlintide

UR - http://www.scopus.com/inward/record.url?scp=84880845903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880845903&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e318235f2cb

DO - 10.1097/MJT.0b013e318235f2cb

M3 - Article

AN - SCOPUS:84880845903

VL - 20

SP - 376

EP - 383

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 4

ER -